Manganese produce a parkinsonism-like illness characterized by movement abnormalities. This condition is not responsive to typical therapies used in the treatment of PD, suggesting an alternative pathway than the typical dopaminergic loss within the substantia nigra. Manganese may accumulate in the basal ganglia, leading to the abnormal movements. A mutation of the SLC30A10 gene, a manganese efflux transporter necessary for decreasing intracellular Mn, has been linked with the development of this Parkinsonism-like disease. The Lewy bodies typical to PD are not seen in Mn-induced parkinsonism. Animal experiments have given the opportunity to examine the consequences of manganese overexposure under controlled conditions.
Manganese(II) sulfate for electrolytic manganese dioxide. Alternatively oxidation of manganese sulfate with potassium permanganate yields the so-called chemical manganese dioxide (CMD). These materials, especially EMD, are used in dry-cell batteries. Manganese(II) sulfate minerals are very rare in the nature and always occur as hydrates. The monohydrate is called szmikite; tetrahydrate = ilesite; hexahydrate (the most rare) = chvaleticeite; pentahydrate = jôkokuite; heptahydrate = mallardite. Manganese(II) sulfate Manganese(II) sulfate usually refers to the inorganic compound with the formula MnSO·HO. This pale pink deliquescent solid is a commercially significant manganese(II) salt. Approximately 260 thousand tonnes of manganese(II) sulfate were produced worldwide in 2005. It